Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants

Abstract

Raltegravir (RAL) is an HIV integrase inhibitor characterized by potent antiretroviral activity, few adverse effects, and lack of cross-resistance to other antiretroviral (ARV) agents. RAL is emerging as a component of effective alternative ARV therapy for those who experience therapeutic failure or intolerance to reverse transcriptase inhibitors (NRTI and NNRTI) and ritonavir (RTV)-boosted protease inhibitor (PI) containing regimens. The combination of RAL with atazanavir (ATV) without a concomitant NRTI-based backbone or the inclusion of RTV may provide an alternative strategy for those unable to tolerate these latter ARV agents. In this report the authors present a case series of treatment-experienced patients managed with RAL + ATV given without a boosting dose of RTV. All patients tolerated this regimen over a course of 25 to 82 weeks, and had good virologic and immunologic outcome with a decrease in HIV RNA levels to <50 copies/mL and a mean CD4 count increase of 234 cells/mm³.

Keywords

raltegravir unboosted atazanavir HIV treatment experienced antiretroviral resistance

References

Grinsztejn B. , Nguyen B-Y. , Katlama C. , et al, and Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007;369:1261-1269.

Murray JM , Emery S. , Kelleher AD , et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007;21:2315-2321.

Markowitz M. , Nguyen BY , Gotuzzo E. , et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125-133.

Cooper DA , Steigbigel RT , Gatell JM , et al. Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-365.

Iwamoto M. , Wenning LA , Mistry GC , et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47:137-140.

DHHS Guidelines for Use of Antiretroviral Agents in HIV-1-Infected Adults and Adoloescents. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGLpdf. Accessed October 10, 2008.

Malan DR , Krantz E. , Wirtz V. , David N. , Hammond J. , McGrath D. , and 089 Study Group. Efficacy and safety of atazanavir, with or without ritonavir, as part of once daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2008;47:161-167.

Zhu L. , Mahnke L. , Persson A. , et al. Pharmacokinetics, safety and tolerability of atazanavir 200, 300, and 400 mg twice daily in healthy subjects Abstract A-952 presented at 48th ICAAC/IDSA 46th annual meeting; October 25-28 , 2008; Washington, DC.

Johnson V. , Brun-Vezinet F. , Clotet B. , et al. Update of the drug resistance mutations in HIV-1: spring 2008. IAS-USA Top HIV Med. 2008;16:62-67. Available at: http://www.iasusa.org/resistance_mutations

10.

Stanford University HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu. Accessed October 10, 2008.

11.

Anderson JA , Jiang H. , Ding X. , et al and AIDS Clinical Trials Group Study 359 Protocol Team. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses. 2008;24:685-694.

12.

Markowitz M. , Morales-Ramirez JO , Nguyen BY , et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1 infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515.

13.

Haas DW , Zala C. , Schrader S. , et al and Protocol AI424-009 Study Group. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized Comparative Pilot Trial. AIDS. 2003;17:1339-1350.